Immunology biotech Agomab Therapeutics and eye-focused SpyGlass Pharma have both unveiled their intentions to go public, in ...

Two more biopharma companies—the hair-growth specialist Veradermics and cancer-focused Eikon Therapeutics—have announced ...

Meanwhile, another $70 million to $80 million of the IPO proceeds is expected to fund the launch a phase 1b study of its ...

With partner Eli Lilly’s help, the radiopharmaceutical drugmaker priced one of the sector’s largest new stock offerings in ...

Hair loss–focused Veradermics and cancer biotech Eikon follow the lead of Aktis Oncology, which last week announced a $318 ...

Investors are eyeing a rebound in the U.S. biotech sector in 2026, as more companies ​are expected to go public amid a ...

Aktis Oncology, which recently had its IPO, has gained substantial backing from Big Pharma mainstay Eli Lilly. Investors ...

Cancer drug developer Aktis Oncology announced on Thursday that it has successfully priced its upsized U.S. initial public ...

A surge in deals and financings had the industry abuzz heading into this year’s J.P. Morgan Healthcare Conference. But some ...

Biotech is dominating the (very) early 2026 deals market, whether that be startup fundings, IPOs, or mergers. Why it matters: ...

TheraVectys SA is considering an initial public offering in Hong Kong, according to people familiar with the matter, a rare ...

Highlights from JPMorgan's 2026 healthcare conference cover patient cash payments for obesity drugs, renewed biotech IPO ...